Abstract
Since 2009, the concepts of axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) have been used, while the radiographic phenotype (r-axSpA) and the non-radiographic phenotype (nr-axSpA) are distinguished. Nowadays, the treatment of nr-axSpA is carried out in the same way as r-axSpA. At the same time, it is obvious that nr-axSpA is more heterogeneous than radiographic, which can determine the peculiarities of patient management tactics. The authors cited 2 clinical cases in which they demonstrated the possibility of achieving persistent drug-free remission at an early (less than 6 months from the first occurrence of disease signs) use of secukinumab in patients with nr-axSpA. The clinical, laboratory and radiological data of two patients meeting the criteria of the SpondyloArthritis International Society are presented in detail. The clinical cases described in this paper are of considerable interest to practitioners since they present the first experience of using this drug in patients with nr-axSpA outside the clinical studies. Also, they can become a part of the clinical experience that will form the basis for further nraxSpA study with the subsequent development of individual clinical recommendations for the treatment of this disease. KEYWORDS: axial spondyloarthritis, non-radiographic axial spondyloarthritis, secukinumab, early treatment, remission. FOR CITATION: Gaydukova I.Z., Mazurov V.I., Inamova O.V. Secukinumab for non-radiographic axial spondyloarthritis. Russian Medical Inquiry. 2021;5(5):294–300 (in Russ.). DOI: 10.32364/2587-6821-2021-5-5-294-300.
Highlights
Изменения, произошедшие в понимании этиологии, патогенеза и клинического течения спондилоартритов (СпА), явились одним из значимых событий ревматологии XXI в. [1,2,3]
it is obvious that nr-axSpA is more heterogeneous than radiographic
which can determine the peculiarities of patient management tactics
Summary
Произошедшие в понимании этиологии, патогенеза и клинического течения спондилоартритов (СпА), явились одним из значимых событий ревматологии XXI в. [1,2,3]. От момента появления первых симптомов заболевания) применении секукинумаба у пациентов с нр-аксСпА. Эффективность терапии оценивали путем применения критерия неактивной болезни согласно индексу активности АС (Ankylosing Spondylitis Disease Activity Score, ASDAS) и СРБ – ASDASСРБ (ASDAS — неактивная болезнь) и путем применения определения и критериев ремиссии Российской группы экспертов по изучению спондилоартритов (ЭкСпА) при ООО АРР [7].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.